Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SciClone Licenses New Ondansetron Forumulation From APR For Chinese, Vietnam Markets

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - California-based SciClone Pharmaceuticals inked an agreement with Switzerland-based Applied Pharma Research to license Ondansetron Rapidflim for China and Vietnam. Under the agreement, SciClone will pay APR $1 million plus milestone payments for marketing rights for 10 years following regulatory approval, according to SciClone

You may also be interested in...



Lost Patent Protection? Move To China, Says Specialty Biotech SciClone

The value of brand in China has helped SciClone consistently grow sales of its branded flagship product Zadaxin even with no IP protection and significant generic competition. Indicated for hepatitis B and hepatitis C, Zadaxin has generated $80 million in sales in China and is the backbone of the small biotech company

Lost Patent Protection? Move To China, Says Specialty Biotech SciClone

The value of brand in China has helped SciClone consistently grow sales of its branded flagship product Zadaxin even with no IP protection and significant generic competition. Indicated for hepatitis B and hepatitis C, Zadaxin has generated $80 million in sales in China and is the backbone of the small biotech company

SciClone's Quarter Sales Growth Marred By FCPA Investigation Of China Operations

HONG KONG - U.S. regulatory authorities have launched an investigation into the China operations of Hong Kong-based and Nasdaq-listed SciClone Pharmaceuticals, a specialty pharmaceutical company

Latest News
See All
UsernamePublicRestriction

Register

SC072361

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel